Short answer
Protagonist Therapeutics, Inc (PTGX) filed its Q3 2026 10-Q quarterly report on Nov 6, 2026 for the quarter ended Sep 30, 2026. Quarterly revenue was $274M (up 5723.6% year over year) with net income of $220M.
Q3 2026 key financials · XBRL
- Revenue
- $274M
- +5723.6% YoY · +28.5% QoQ
- Net income
- $220M
- +659.3% YoY · +35.1% QoQ
- Operating margin
- 79.6%
- EPS (diluted)
- $3.08
- +596.8% YoY · +33.9% QoQ
Source: XBRL data from the Protagonist Therapeutics, Inc (PTGX) Q3 2026 10-Q on SEC EDGAR. USD.
Protagonist Therapeutics, Inc Q3 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Revenue $274.4M, up from $4.7M YoY, primarily from Takeda opt-out and milestone payments
- Net income $220.0M vs $39.3M loss YoY, operating margin 79.6% vs negative 985.0%
- PN-881 R&D $10.4M, strongest clinical program; MIMRYLO R&D $3.2M, down 85% YoY
- Cash, equivalents and securities $834.6M vs $646.0M at December 31, 2025; operating cash flow $146.9M
- $5.8M stock repurchases; R&D spending expected to rise for PN-881, PN-477o, PN-458 and PN-8047 development
Risk Factors
- No material changes from the December 31, 2025 Form 10-K risk factors
- Carried-forward business risk: risks described throughout the September 30, 2026 Form 10-Q and other SEC filings
- Prior-quarter changes: risks identified in the June 30, 2026 Form 10-Q remain the latest updates
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Protagonist Therapeutics, Inc quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.